New evidence supporting lung cancer screening with low dose CT & surgical implications

• Published in: European journal of surgical oncology Vol. 46; no. 6; pp. 982 - 990
• Main Authors: Dezube, Aaron R., Jaklitsch, Michael T.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-06-2020
• Subjects: Cost-Benefit Analysis; Early Detection of Cancer - methods; Humans; LDCT; Low dose computed tomography; Lung cancer; Lung cancer screening; Lung Neoplasms - diagnosis; Lung Neoplasms - surgery; Mass Screening - methods; Radiation Dosage; Risk Factors; Thoracotomy - methods; Tomography, X-Ray Computed - methods; NHIS; RR; AATS; RCT; VATS; NCCN; Lung cancer; Low dose computed tomography; I-ELCAP; LDCT; HR; Lung cancer screening; ITALUNG; PLCO; USPSTF; LLP; NNS; STS; NELSON; SEER; NSCLC; CI; CMS; CISNET; MILD; ACS; CT; AAFP; ALA; SBRT; SABR; UKLS; NLST; CXR; LUSI; DANTE
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2020.02.015

Lung cancer is the leading cause of cancer-death worldwide. The U.S. Preventative Services Task Force (USPTSF) approved screening for current or former smokers aged 55–80 based on the results of the National Lung Screening trial (NLST). Following the NLST, new evidence has emerged from clinical trials and updates to previous trials prior to the anticipated update to the USPSTF guideline. We review the new evidence on lung cancer screening with low dose computed tomography (LDCT) and the surgical implications.
A review of new literature was performed pertaining to lung cancer screening since implementation of UPSTF guidelines. Articles for inclusion were identified by both authors’, then search of the Pubmed and Cochrane database was performed from January 1st, 2013 through February 4th, 2020 using the MeSH search terms: “lung cancer”; “screening”; “low dose CT”. The results of these studies are summarized.
We identified multiple prospective randomized control trials and meta-analysis since the NLST supporting lung cancer-specific mortality with screening. We identified new nodule classification systems and the development of risk-models which may reduce false positive rates and identify high risk patients not currently eligible for screening. Finally, we discussed the surgical implications of screening.
New data supports NLST findings and show ongoing benefit to LDCT for lung cancer screening. Standardized LDCT screening classification has been shown to reduce harm and lower false positive rates. Further study is needed regarding use of risk-modeling. Screening will require an increase in the thoracic workforce to accommodate the amount of surgically operable cancers.